capivasertib (Truqap)

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

Mechanism of action

More general terms

References

  1. John A Capivasterib Meets Primary Endpoint in Phase 3 Breast Cancer Trial. Clinical Advances in Breast Cancer. Nov 14, 2022 https://www.mdalert.com/ms/cabreast/article/capivasterib-meets-primary-endpoint
  2. 2.0 2.1 Bankhead C First AKT Inhibitor Approved for Advanced Breast Cancer. Capivasertib plus fulvestrant doubled progression-free survival versus fulvestrant-placebo MedPage Today November 17, 2023 https://www.medpagetoday.com/hematologyoncology/breastcancer/107431

Database